Form 4: ALX Oncology Holdings Inc. Executive Acquires 90,000 Stock Options

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., acquired 90,000 employee stock options on April 11, 2025, according to a recent SEC filing.

Summary

• On April 15, 2025, Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on April 11, 2025, where Ms. Pinto acquired 90,000 employee stock options.
• The exercise price of these options is $0.49 per share.
• The options vest on April 11, 2026, and expire on April 11, 2035.
• Following the reported transaction, Ms. Pinto directly owns 90,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an executive's stock option grant, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency into the transactions of company executives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued employment and market value of the stock.

Stakeholder Impact

• The acquisition of stock options by a company executive can have a minor positive impact on shareholder sentiment, as it suggests confidence in the company's future.

Key Dates

Keywords

ALX Oncology Holdings Inc, Shelly Pinto, stock options, Form 4, SEC filing, insider transaction, executive compensation